This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Quetiapine and hypothyroidism

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A Chinese retrospective cohort study (n=2022) found acute phase quetiapine treatment is linked to an increased risk of developing new-onset hypothyroidism compared to placebo (15% vs 3.5%, respectively, RR 4.01; 95% CI, 2.86-5.64) with a clear dose-response association:

  • a total of 2022 eligible patients were included in the final analysis
    • sixty patients (15.0%) in the quetiapine group developed hypothyroidism, while 56 patients (3.5%) in the nonquetiapine group developed hypothyroidism
    • relative risk (95% confidence interval) of developing hypothyroidism for quetiapine use was 4.01 (2.86-5.64) after adjusting for several potential confounding factors
    • a strong dose-response association between quetiapine use and risk of developing hypothyroidism was observed: adjusted relative risks (95% confidence intervals) were 1.00 (0.25-2.59), 4.22 (2.80-6.25) and 5.62 (3.66-8.38), respectively, for low-, medium- and high-dose quetiapine, as compared with no quetiapine
  • study authors concluded that:
    • acute phase quetiapine treatment for schizophrenia patients was strongly associated with increased risk of developing new-onset hypothyroidism, with a clear dose-response association

Reference:

  1. Zhao, Y, Wen, SW, Li, M, et al. Dose–response association of acute-phase quetiapine treatment with risk of new-onset hypothyroidism in schizophrenia patients. Br J Clin Pharmacol. 2021; 87( 12): 4823-4830. https://doi.org/10.1111/bcp.14928

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.